DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for premenstrual tension — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePremenstrual tension maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedDanazolApproved drugapprovedMedroxyprogesterone AcetateApproved drug
Structures already discussed alongside premenstrual tension in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
Sex Hormone-binding globulin mutant E176K — Danazol has a real, experimentally solved structure in complex with this target (PDB 6ULB, 1.75 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet qa1drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6ULB · 1.75 Å · ligand Danazol (QA1). Experimental structure, not a prediction.
What the evidence adds up to
Forty-three women with premenstrual tension took part in a placebo-controlled crossover study of spironolactone and medroxyprogesterone acetate. Placebo, spironolactone, and medroxyprogesterone acetate all significantly improved a mood index score. Spironolactone and medroxyprogesterone acetate were both significantly better than placebo at relieving symptoms, with a p value of less than 0.05. No response rates or survival figures are given because the study measured symptom scores, not those endpoints.
A separate paper from 1986 describes the diagnostic features of premenstrual tension syndrome, emphasising its time-limited course and the fact that it can coexist with or exacerbate other psychological distress. Four case histories are presented to illustrate diagnostic complexity. No treatment data are reported in that paper.
A 1963 report describes the development of research diagnostic criteria for premenstrual tension syndrome using data from 42 women who had severe PMTS but were well at other times. Two rating scales were devised: a 36-item self-report questionnaire and a 10-item scale for use by a therapist or researcher. The authors state that after further evaluation and validation, these instruments may permit more useful comparisons of data on aetiology and treatment. No treatment outcomes are reported.
What is still missing is a large, modern, placebo-controlled trial that reports response rates rather than mean symptom scores, and that accounts for the diagnostic heterogeneity described in the 1986 paper. No validated stratification method for patient subtypes has been tested in a treatment trial. Funding for such a trial, and agreement on a standardised diagnostic instrument, remain absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
BJOG An International Journal of Obstetrics & Gynaecology · 1987 · 68 citations
A clinical trial using danazol for the treatment of premenstrual tension
AbstractForty women with premenstrual tension received either placebo, 100, 200 or 400 mg danazol daily for 3 months in a pilot study arranged as a double-blind trial. Thirteen patients withdrew by the third month usually because they complained of no improvement. They had significantly higher pretrial symptom scores than those who continued. In patients treated with danazol, symptom scores for breast pain during the second and third months and for irritability, anxiety and lethargy during the third month were significantly (P less than 0.05) lower than scores in those given placebo. Most symptoms improved on placebo in the first month but by the third month only three remained improved. In contrast eight symptoms were improved on 200 mg danazol by the third month. By the end of the trial more than 75% of patients who were still taking danazol were essentially free of breast pain, lethargy, anxiety and increased appetite, but results for other common symptoms were no better than with placebo.
International Journal of Gynecology & Obstetrics · 1991 · 32 citations
Premenstrual tension: A placebo‐controlled efficacy study with spironolactone and medroxyprogesterone acetate
AbstractForty-three healthy women with a characteristic history of premenstrual tension participated in a placebo controlled, crossover study. The effects of spironolactone (Aldactone) and medroxyprogesterone acetate (Gestapuran) on ten symptoms of premenstrual tension were evaluated. Placebo tablets as well as spironolactone and medroxyprogesterone acetate significantly improved a mood index score (which is a generally accepted method to measure premenstrual symptoms). Spironolactone and medroxyprogesterone acetate were however both significantly (P less than 0.05) better than placebo in relieving the symptoms.
AbstractThe presence of a premenstrual tension syndrome (PMTS) should be considered during the clinical assessment of any women of childbearing age with intermittent or fluctuating psychological symptoms. Appropriate identification of this disorder depends on knowledge of its specific diagnostic features, most particularly its time-limited course. The clinician must also be aware that the syndrome can coexist with, exacerbate, or be exacerbated by other psychological distress or illness. Through the presentation of four case histories, the authors discuss the diagnostic complexities of PMTS and the treatment implications of a diagnosis of PMTS.
AbstractResearch diagnostic criteria for premenstrual tension syndrome (PMTS) are developed using data collected from a study of 42 women who were suffering from severe PMTS but were well at other times.Two specific scales are also devised for rating the severity of PMTS, a 36-item self-report questionnaire and a 10item scale for use by therapisvresearcher.It is proposed that after further evaluation and validation, these instruments may permit more useful comparisons of data on the etiology and treatment of this disorder.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
